PriceTargets.com logo

Cellectis - CLLS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $9.80
  • Forecasted Upside: 212.10%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.14 As of 01/26/2023 01:00 AM ET
▼ -0.09 (-2.79%)

This chart shows the closing price for CLLS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cellectis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLLS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLLS

Analyst Price Target is $9.80
▲ +212.10% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Cellectis in the last 3 months. The average price target is $9.80, with a high forecast of $24.00 and a low forecast of $2.00. The average price target represents a 212.10% upside from the last price of $3.14.

This chart shows the closing price for CLLS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 investment analysts is to hold stock in Cellectis. This rating has held steady since May 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
7/31/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
10/29/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/28/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/27/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/19/2023JMP SecuritiesLower TargetMarket Outperform$11.00 ➝ $6.00Low
12/14/2022CitigroupLower Target$36.00 ➝ $24.00Low
8/18/2022CitigroupBoost Target$34.00 ➝ $36.00Low
5/24/2022The Goldman Sachs GroupLower TargetSell$3.00 ➝ $2.00Medium
5/18/2022Robert W. BairdUpgradeNeutral ➝ Outperform$10.00High
5/13/2022BarclaysLower Target$9.00 ➝ $7.00High
1/6/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$39.00 ➝ $16.00High
12/14/2021JMP SecuritiesReiterated RatingBuyHigh
12/14/2021Robert W. BairdReiterated RatingHold$10.00High
12/8/2021JMP SecuritiesReiterated RatingBuy$20.00Low
11/30/2021JMP SecuritiesInitiated CoverageOutperform$20.00Medium
11/8/2021William BlairDowngradeOutperform ➝ Market PerformMedium
10/17/2021Robert W. BairdReiterated RatingHold$10.00Medium
10/8/2021Robert W. BairdDowngradeOutperform ➝ Neutral$39.00 ➝ $10.00High
8/20/2021JonestradingReiterated RatingBuy$30.00Medium
6/3/2021OppenheimerInitiated CoverageBuy$33.00Low
6/1/2021William BlairReiterated RatingBuyHigh
5/27/2021Robert W. BairdReiterated RatingBuy$39.00High
5/4/2021GuggenheimReiterated RatingBuy ➝ NeutralN/A
4/29/2021Robert W. BairdReiterated RatingBuy$39.00High
4/28/2021GuggenheimDowngradeBuy ➝ NeutralHigh
3/16/2021Robert W. BairdUpgradeNeutral ➝ Outperform$23.00 ➝ $39.00High
3/8/2021William BlairReiterated RatingOutperformHigh
11/18/2020William BlairReiterated RatingBuyMedium
10/15/2020Robert W. BairdDowngradeOutperform ➝ NeutralHigh
8/19/2020CitigroupUpgradeNeutral ➝ Buy$15.00 ➝ $32.00High
8/6/2020OppenheimerReiterated RatingBuy$33.00Medium
7/7/2020Robert W. BairdLower TargetOutperform$28.00 ➝ $21.00High
5/11/2020Robert W. BairdInitiated CoverageOutperform$20.00Medium
5/7/2020OppenheimerReiterated RatingBuy$35.00High
3/6/2020CitigroupBoost TargetNeutral$14.00 ➝ $16.00Medium
3/6/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$15.00 ➝ $11.00High
2/19/2020BTIG ResearchBoost TargetBuy$37.00 ➝ $39.00High
1/13/2020William BlairReiterated RatingBuyHigh
12/16/2019Nomura SecuritiesReiterated RatingBuy$73.00Low
8/12/2019The Goldman Sachs GroupSet TargetHold$20.00High
8/9/2019BTIG ResearchInitiated CoverageBuy ➝ Buy$37.00High
5/24/2019CitigroupReiterated RatingNeutral ➝ Neutral$22.00Medium
3/13/2019William BlairInitiated CoverageOutperformMedium
3/13/2019BarclaysReiterated RatingBuy$50.00High
3/11/2019CitigroupLower TargetNeutral$37.00 ➝ $22.00High
12/19/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$25.00High
11/25/2018OppenheimerSet TargetBuy$44.00Low
7/16/2018BarclaysInitiated CoverageOverweight$50.00High
6/12/2018OppenheimerBoost TargetOutperform ➝ Outperform$40.00 ➝ $44.00Low
3/16/2018GuggenheimInitiated CoverageNeutral ➝ NeutralHigh
3/14/2018Nomura SecuritiesBoost TargetBuy$73.00High
(Data available from 1/27/2018 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/1/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/31/2022
  • 2 very positive mentions
  • 14 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
8/30/2022
  • 1 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/29/2022
  • 4 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2023

Current Sentiment

  • 2 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

  • No positive mentions tracked during this time.

Very Positive

Cellectis logo
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Read More

Today's Range

Now: $3.14
Low: $3.06
High: $3.20

50 Day Range

MA: $2.53
Low: $1.85
High: $3.84

52 Week Range

Now: $3.14
Low: $1.83
High: $6.74

Volume

22,247 shs

Average Volume

154,101 shs

Market Capitalization

$143.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.95

Frequently Asked Questions

What sell-side analysts currently cover shares of Cellectis?

The following equities research analysts have issued reports on Cellectis in the last year: Barclays PLC, Citigroup Inc., JMP Securities, Robert W. Baird, StockNews.com, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for CLLS.

What is the current price target for Cellectis?

5 Wall Street analysts have set twelve-month price targets for Cellectis in the last year. Their average twelve-month price target is $9.80, suggesting a possible upside of 212.1%. Citigroup Inc. has the highest price target set, predicting CLLS will reach $24.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $2.00 for Cellectis in the next year.
View the latest price targets for CLLS.

What is the current consensus analyst rating for Cellectis?

Cellectis currently has 1 sell rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CLLS, but not buy more shares or sell existing shares.
View the latest ratings for CLLS.

What other companies compete with Cellectis?

Other companies that are similar to Cellectis include INmune Bio, Vaxart, Athira Pharma, BioAtla and Ikena Oncology. Learn More about companies similar to Cellectis.

How do I contact Cellectis' investor relations team?

Cellectis' physical mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company's listed phone number is (318) 169-1600 and its investor relations email address is [email protected] The official website for Cellectis is www.cellectis.com. Learn More about contacing Cellectis investor relations.